article thumbnail

How are mRNA vaccines changing drug discovery?

Tebu Bio: Drug Discovery

mRNA vaccines are developing very quickly with dozens of ongoing clinical trials against cancers or infectious diseases (e.g. Recombinant monoclonal antibody (mAB) based treatments have proven their efficacy. HIV or more recently SARS-Cov-2). Pre-clinical and clinical trials […]

Vaccine 52
article thumbnail

ChEMBL 34 is out!

The ChEMBL-og

71 out of the 882 newly added EMA drugs are only authorised by EMA, rather than from other regulatory bodies e.g. FDA. University of Dundee: T. 1813 bioactivities in total have been added.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Inside The Altascientist Issue 41: Immunomodulation Assessments for Clinical Trials–Sophisticated Bioanalytical Approaches to Support Complex Modalities

Alta Sciences

This issue also covers classes of immunomodulators, including monoclonal antibodies, CAR-T cells, and vaccines; immunotherapy trials, focusing on complex study designs and diverse patient populations; and bioanalytical methods and assays, including pharmacokinetics and anti-drug antibodies (ADA).

article thumbnail

Use of Ultra-High-Throughput Screening in Discovery of COVID-19 Virus Structure

PerkinElmer

The virus, which can cause a severe form of pneumonia and lead to acute respiratory distress, currently has no FDA-approved targeted therapeutic or vaccine. Following the high-throughput screening were cell-based assays, which demonstrated that the identified leads had strong anti-viral action.

Virus 52
article thumbnail

A Bioanalysis Partner You Can Trust

Alta Sciences

VIEW FACT SHEET Need more guidance? Send us a message. Send us a message.